Urothelial carcinoma in the prostatic urethra and prostate: current controversies

References

• Ende N, Woods LP, Shelley HS. Carcinoma originating in ducts surrounding the prostatic urethra. Am. J. Clin. Pathol.40, 183–189 (1963).
   PubMed Web of Science ®Google Scholar
• Hall RH, Robinson MC. Transitional cell carcinoma of the prostate. Eur. Urol. Update Series7(1), 1–7 (1998).
   Google Scholar
• Reese JH, Freiha FS, Gelb AB, Lum BL, Torti FM. Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J. Urol.147(1), 92–95 (1992).
   PubMed Web of Science ®Google Scholar
• Palou J, Baniel J, Klotz L et al.Urothelial Carcinoma of the Prostate. Health Pubication Ltd, Paris, France 309–334 (2006).
   Google Scholar
• Rikken CH, van Helsdingen PJ, Kazzaz BA. Are biopsies from the prostatic urethra useful in patients with superficial bladder carcinoma? Br. J. Urol.59(2), 145–147 (1987).
   PubMedGoogle Scholar
• Solsona E, Iborra I, Ricos JV et al. Recurrence of superficial bladder tumors in prostatic urethra. Eur. Urol.19(2), 89–92 (1991).
   PubMedGoogle Scholar
• Davis JW, Sheth SI, Doviak MJ, Schellhammer PF. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J. Urol.167(2 Pt 1), 494–500; discussion 501 (2002).
   PubMed Web of Science ®Google Scholar
• Herr HW, Donat SM. Prostatic tumor relapse in patients with superficial bladder tumors: 15-year outcome. J. Urol.161(6), 1854–1857 (1999).
   PubMed Web of Science ®Google Scholar
• Nixon RG, Chang SS, Lafleur BJ, Smith JJ, Cookson MS. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J. Urol.167(2 Pt 1), 502–505 (2002).
   PubMed Web of Science ®Google Scholar
• Kefer JC, Voelzke BB, Flanigan RC, Wojcik EM, Waters WB, Campbell SC. Risk assessment for occult malignancy in the prostate before radical cystectomy. Urology66(6), 1251–1255 (2005).
   PubMed Web of Science ®Google Scholar
• Zincke H, Utz DC, Farrow GM. Review of Mayo Clinic experience with carcinoma in situ. Urology26(Suppl. 4), 39–46 (1985).
   PubMed Web of Science ®Google Scholar
• Revelo MP, Cookson MS, Chang SS, Shook MF, Smith JA Jr, Shappell SB. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J. Urol.171(2 Pt 1), 646–651 (2004).
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Tsuneyoshi M, Naito S, Kumazawa J. An adequate sampling of the prostate to identify prostatic involvement by urothelial carcinoma in bladder cancer patients. J. Urol.149(2), 318–321 (1993).
   PubMed Web of Science ®Google Scholar
• Liedberg F, Chebil G, Davidsson T, Malmstrom PU, Sherif A, Mansson W. Transitional cell carcinoma of the prostate in cystoprostatectomy specimens. Aktuelle Urol.34(5), 333–336 (2003).
   PubMedGoogle Scholar
• Donat SM, Wei DC, McGuire MS, Herr HW. The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J. Urol.165(5), 1580–1584 (2001).
   PubMed Web of Science ®Google Scholar
• Wood DP Jr, Montie JE, Pontes JE, Levin HS. Identification of transitional cell carcinoma of the prostate in bladder cancer patients: a prospective study. J. Urol.142(1), 83–85 (1989).
   PubMed Web of Science ®Google Scholar
• Njinou Ngninkeu B, Lorge F, Moulin P, Jamart J, Van Cangh PJ. Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. J. Urol.169(1), 149–152 (2003).
   PubMedGoogle Scholar
• Esrig D, Freeman JA, Elmajian DA et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J. Urol.156(3), 1071–1076 (1996).
   PubMed Web of Science ®Google Scholar
• Pagano F, Bassi P, Ferrante GL et al. Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. J. Urol.155(1), 244–247 (1996).
   PubMed Web of Science ®Google Scholar
• Donat SM, Genega EM, Herr HW, Reuter VE. Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. J. Urol.165(4), 1117–1120 (2001).
   PubMed Web of Science ®Google Scholar
• Liedberg F, Chebil G, Mansson W. Hematogenous dissemination of transitional cell carcinoma in the bladder to the prostate. Scand. J. Urol. Nephrol.37(4), 359–360 (2003).
   PubMed Web of Science ®Google Scholar
• Solsona E, Iborra I, Rubio J, Casanova J, Almenar S. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. Br. J. Urol. Int.94(9), 1258–1262 (2004).
   Google Scholar
• Wittekind C, Greene FL, Hutter RVP, Henson TE, Sobin LH (Eds). TNM Supplement: A Commentary on Uniform Use (3rd Edition). Wiley-Liss, Geneva, Switzerland 67–69 (2003).
   Google Scholar
• Shen SS, Lerner SP, Muezzinoglu B, Truong LD, Amiel G, Wheeler TM. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum. Pathol.37(6), 726–734 (2006).
   PubMed Web of Science ®Google Scholar
• Hillyard RW Jr, Ladaga L, Schellhammer PF. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette–Guerin. J. Urol.139(2), 290–293 (1988).
   PubMed Web of Science ®Google Scholar
• Bretton PR, Herr HW, Whitmore WF Jr et al. Intravesical bacillus Calmette–Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra. J. Urol.141(4), 853–856 (1989).
   PubMedGoogle Scholar
• Schellhammer PF, Ladaga LE, Moriarty RP. Intravesical bacillus Calmette-Guerin for the treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder. J. Urol.153(1), 53–56 (1995).
   PubMed Web of Science ®Google Scholar
• Palou J, Xavier B, Laguna P, Montlleo M, Vicente J. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette–Guerin therapy without previous transurethral resection of the prostate. Urology47(4), 482–484 (1996).
   PubMed Web of Science ®Google Scholar
• Canda AE, Tuzel E, Mungan MU, Yorukoglu K, Kirkali Z. Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder. Eur. Urol.45(4), 465–469; discussion 469–470 (2004).
   PubMedGoogle Scholar
• Palou J, López H, Millán F, Oliver A, Salvador J, Vicente J. Effect of intravesical instillations of BCG on total PSA. Preliminary results. Br. J. Urol. Int.86(Suppl. 3), 254 (2000).
   Google Scholar
• Orihuela E, Herr HW, Whitmore WF Jr. Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG. Urology34(5), 231–237 (1989).
   PubMedGoogle Scholar
• Solsona E, Iborra I, Ricos JV, Monros JL, Casanova JL, Almenar S. The prostate involvement as prognostic factor in patients with superficial bladder tumors. J. Urol.154(5), 1710–1713 (1995).
   PubMed Web of Science ®Google Scholar
• Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J. Urol.171(5), 1830–1834 (2004).
   PubMed Web of Science ®Google Scholar
• Hautmann RE, Stein JP. Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol. Clin. North Am.32(2), 177–185 (2005).
   PubMed Web of Science ®Google Scholar
• Freeman JA, Esrig D, Stein JP, Skinner DG. Management of the patient with bladder cancer. Urethral recurrence. Urol. Clin. North Am.21(4), 645–651 (1994).
   PubMed Web of Science ®Google Scholar
• Stein JP, Clark P, Miranda G, Cai J, Groshen S, Skinner DG. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J. Urol.173(4), 1163–1168 (2005).
   PubMed Web of Science ®Google Scholar
• Freeman JA, Tarter TA, Esrig D et al. Urethral recurrence in patients with orthotopic ileal neobladders. J. Urol.156(5), 1615–1619 (1996).
   PubMed Web of Science ®Google Scholar
• Lebret T, Herve JM, Barre P et al. Urethral recurrence of transitional cell carcinoma of the bladder. Predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatocystectomy. Eur. Urol.33(2), 170–174 (1998).
   PubMed Web of Science ®Google Scholar
• Iselin CE, Robertson CN, Webster GD, Vieweg J, Paulson DF. Does prostate transitional cell carcinoma preclude orthotopic bladder reconstruction after radical cystoprostatectomy for bladder cancer? J. Urol.158(6), 2123–2126 (1997).
   PubMed Web of Science ®Google Scholar
• Kitamura T, Moriyama N, Shibamoto K et al. Urethrectomy is harmful for preserving potency after radical cystectomy. Urol. Int.42(5), 375–379 (1987).
   PubMedGoogle Scholar
• Tomic R, Sjodin JG. Sexual function in men after radical cystectomy with or without urethrectomy. Scand. J. Urol. Nephrol.26(2), 127–129 (1992).
   PubMed Web of Science ®Google Scholar
• Schellhammer PF, Bean MA, Whitmore WF Jr. Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J. Urol.118(3), 399–403 (1977).
   PubMed Web of Science ®Google Scholar
• Solsona E, Iborra I, Dumont R, Rubio J, Casanova JL, Almenar S. Risk groups in patients with bladder cancer treated with radical cystectomy: statistical and clinical model improving homogeneity. J. Urol.174(4 Pt 1), 1226–1230 (2005).
   PubMed Web of Science ®Google Scholar